✦ LIBER ✦

A Phase I/II Trial of Combination of PKC412 and 5-azacytidine (AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

✍ Scribed by Nazha, Aziz; Kantarjian, Hagop; Borthakur, Gautam; Kadia, Tapan; Faderl, Stefan; Ravandi, Farhad; Estrov, Zeev; Jabbour, Elias; Quintas-Cardama, Alfonso; Cortes, Jorge

Book ID: 122220809
Publisher: Elsevier
Year: 2013
Tongue: English
Weight: 76 KB
Volume: 13
Category: Article
ISSN: 2152-2650
DOI: 10.1016/j.clml.2013.07.078

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pilot study of combination transcription

Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome

✍ Maslak, P; Chanel, S; Camacho, L H; Soignet, S; Pandolfi, P P; Guernah, I; Warre 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 120 KB

5-Azacytidine for the treatment of patie

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis

✍ Czibere, A; Bruns, I; Kröger, N; Platzbecker, U; Lind, J; Zohren, F; Fenk, R; Ge 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 253 KB

Phase I/II Trial Assessing Bortezomib an

Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

✍ Berenson, J. R. 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 103 KB

Phase I/II trial assessing bendamustine

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

✍ Berenson, James R.; Yellin, Ori; Bessudo, Alberto; Boccia, Ralph V.; Noga, Steph 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 304 KB

Results of a multicenter phase II trial

Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib

✍ Florian Heidel; Jorge Cortes; Frank G. Rücker; Walter Aulitzky; Laurie Letvak; T 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

Clofarabine in combination with a standa

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

✍ Willemze, R.; Suciu, S.; Muus, P.; Halkes, C. J. M.; Meloni, G.; Meert, L.; Karr 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 197 KB